Paramyotonia Congenita
National Organization for Rare Disorders, Inc.
Synonyms
- Eulenburg Disease
- Myotonia Congenita Intermittens
- Paralysis Periodica Paramyotonica
- Paramyotonia Congenita of Von Eulenburg
- Von Eulenburg Paramyotonia Congenita
Disorder Subdivisions
General Discussion
Paramyotonia congenita is a rare muscular disorder inherited as an autosomal dominant trait. This nonprogressive disorder is characterized by a condition in which the muscles do not relax after contracting (myotonia). Symptoms can be triggered by exposure to the cold. There are also intermittent periods of a type of paralysis in which there is no muscle tone (flaccid paresis). This condition does not necessarily coincide with exposure to cold temperatures or myotonia. There is no wasting (atrophy) or increase in bulk (hypertrophy) of muscles with this disorder.
Symptoms
Symptoms include muscle stiffness and weakness, mostly in the face, neck and upper extremities. The muscles are slow to relax after contracting (myotonia). This condition may become worse with exposure to cold.
Paramyotonia congenita is usually apparent during infancy and is not progressive. Individuals with this disorder do not have wasting of muscles (atrophy) or an increase of muscle bulk (hypertrophy).
Causes
This condition is transmitted as an autosomal dominant genetic trait. The malfunctioning gene has been tracked to the long arm of chromosome 17 (17q23.1-q25.3)
Chromosomes, which are present in the nucleus of human cells, carry the genetic information for each individual. Human body cells normally have 46 chromosomes. Pairs of human chromosomes are numbered from 1 through 22 and the sex chromosomes are designated X and Y. Males have one X and one Y chromosome and females have two X chromosomes. Each chromosome has a short arm designated "p" and a long arm designated "q". Chromosomes are further sub-divided into many bands that are numbered. For example, "chromosome 17q23.1-q25.3" refers to a region on the long arm of chromosome 17 between bands 23.1 and 25.3. The numbered bands specify the location of the thousands of genes that are present on each chromosome.
Genetic diseases are determined by the combination of genes for a particular trait that are on the chromosomes received from the father and the mother.
All individuals carry a few abnormal genes. Parents who are close relatives (consanguineous) have a higher chance than unrelated parents to both carry the same abnormal gene, which increases the risk to have children with a recessive genetic disorder.
Dominant genetic disorders occur when only a single copy of an abnormal gene is necessary for the appearance of the disease. The abnormal gene can be inherited from either parent, or can be the result of a new mutation (gene change) in the affected individual. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child.
Affected Populations
Paramyotonia congenita is a very rare disorder that affects males and females in equal numbers. A detailed study conducted in Germany concluded that the incidence of PMC was between 1 in 180,000 and 1 in 350,000. They note that the distribution of this disorder is not uniform since they found a region of the country in which the incidence was 1 in 8000.
Three large families with multiple generations of affected members have accounted for at least 60 patients with paramyotonia congenita.
Related Disorders
Symptoms of the following disorders can be similar to those of Paramyotonia Congenita. Comparisons may be useful for a differential diagnosis:
Hyperkalemic Periodic Paralysis is rare disorder inherited as an autosomal dominant trait and typically detected during infancy. This disorder is characterized by periodic muscle weakness with or without muscles that do not relax after contracting (myotonia). Patients may have attacks once a week or several times a day. Typically the periods of muscle weakness last from one half an hour to an hour. This weakness may be found in the calves or thighs of the legs, lower back, arms, neck and/or eyelids. Periods of muscle weakness usually follow rest after exercise, hunger, infection, exposure to the cold and/or emotional stress. Permanent weakness and wasting of muscles may develop later on.
Myotonic Dystrophy is a rare disorder inherited as an autosomal dominant trait. This disorder involves the muscles, vision, and endocrine glands. Myotonic Dystrophy usually begins during young adulthood and is marked initially by an inability to relax muscles after contraction. Loss of muscle strength, mental deficiency, cataracts, reduction of testicular function, and frontal baldness are also symptomatic of this disorder. (For more information on this disorder, choose "Myotonic Dystrophy" as your search term in the Rare Disease Database.)
Thomsen Disease is a rare disorder inherited as an autosomal dominant trait. This neuromuscular disorder usually begins early in life. Difficulty in initiating movement combined with slowness of muscle relaxation are the primary symptoms. Muscle stiffness of the entire body may also occur. Thomsen Disease is generally a nonprogressive disorder. (For more information on this disorder, choose "Thomsen Disease" as your search term in the Rare Disease Database.)
Standard Therapies
Diagnosis When paramyotonia congenita is suspected, a test is administered to test the capacity of muscles to conduct electricity (electromyography).
Treatment The aim of treatment is to reduce the intensity of acute symptoms and to prevent, as far as possible, further attacks. Some attacks are so mild that treatment is not necessary. However, in other instances drug therapy is required.
Some patients with paramyotonia congenita may benefit from acetazolamide or thiazide diuretic drugs to reduce the number of paralytic attacks. Treatment with the drug tocainide may help reduce the cold-induced symptoms in some patients.
Genetic counseling may be of benefit for patients and their families. Other treatment is symptomatic and supportive.
Investigational Therapies
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222 TTY: (866) 411-1010 Email: prpl@cc.nih.gov
For information about clinical trials sponsored by private sources, contact: www.centerwatch.com
References
McKusick VA, ed. Online Mendelian Inheritance in Man (OMIM). Baltimore, MD: The Johns Hopkins University Press; Paramyotonia Congenita of Von Eulenburg; PMC. Entry No: 168300; Last Edit: 8/26/2005.
TEXTBOOKS Kasper, DL, Fauci AS, Longo DL, et al., eds. Harrison’s Principles of Internal Medicine. 16th ed. McGraw-Hill Companies. New York, NY; 2005:2526; 2537.
Rowland LP, ed. Merritt’s Neurology. 10th ed. Lippincott Williams & Wilkins. Philadelphia, PA. 2000:749.
Rimoin D, Connor JM, Pyeritz RP, Korf BR, eds. Emory and Rimoin’s Principles and Practice of Medical Genetics. 4th ed. Churchill Livingstone. New York, NY; 2002:3377-82.
JOURNAL ARTICLES Weber MA, Nielles-Vallespin S, Huttner HB, Worhle JC, et al. Radiology. 2006;240:489-500.
Kurihara T. New classification and treatment for myotonic disorders. Intern Med. 2005;44:1027-32.
Vicart S, Sternberg D, Fontaine B, Meola G. Human skeletal muscle sodiym channelopathies. Neurol Sci. 2005;26:194-202
Fredericson M, Kim BJ, Date ES. Disabling foot cramping in a runner secondary to paramyotonia congenita: a case report. Foot Ankle Int. 2004;25
Kuntzer T. [Electrophysiological testing in muscle channelopathies] Rev Neurol (Paris). 2004;160(5 Pt 2):S49-54. French.
FROM THE INTERNET Mosenkis A. Hyperkalemic periodic paralysis. Medical Encyclopedia. MedlinePlus. Update Date: 8/5/2004. 4pp. www.nlm.nih.gov/medlineplus/ency/article/000316.htm
Frequently Asked Questions about Paramyotonia Congenita. Periodic Paralysis News Desk. Last updated March 2006. 4pp. www.hkpp.org/faq/pmc.html
Emery AEH. Myotonias. Muscular Dystrophy Campaign. 2004. 3pp. www.muscular-dystrophy.org/information_resources/factsheets/medical_conditions_factsheets/myotonias.html
Resources
Muscular Dystrophy Association
3300 E. Sunrise Dr Tucson, AZ 85718 USA Tel: 5205292000 Fax: 5205295300 Tel: 8003444863 Email: mda@mdausa.org Internet: http://www.mdausa.org
Muscular Dystrophy Canada
900-2345 Yonge Street Toronto Ontario, Intl M4P 2E5 Canada Tel: 416-488-0030 Fax: 416-488-7523 Tel: (866)-MUSCLE-8 Email: info@muscle.ca Internet: http://www.muscle.ca
Muscular Dystrophy Campaign
7-11 Prescott Place London, SW4 6BS United Kingdom Email: info@muscular-dystrophy.org Internet: http://www.muscular-dystrophy.org
NIH/National Arthritis and Musculoskeletal and Skin Diseases Information Clearinghouse
1 AMS Circle Bethesda, MD 20892-3675 USA Tel: 3014954484 Fax: 3017186366 Tel: 8772264267 TDD: 3015652966 Email: NIAMSinfo@mail.nih.gov Internet: http://www.niams.nih.gov
Muscular Dystrophy Association of New Zealand, Inc.
PO Box 23-047 Papatoetoe Auckland, New Zealand Tel: 09 2787216 Fax: 09 2777540 Tel: 0800800337 Email: nzmda@nzmda.ak.planet.gen.nz
Muscular Dystrophy Association (Australia)
GPO Box 9932 Melbourne, Intl 3001 Australia Tel: 61 3 9320 9555 Fax: 61 3 9320 9595 Tel: 1 800 656 632 Email: info@mda.org.au Internet: http://www.mda.org.au
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). A copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
The information provided in this report is not intended for diagnostic purposes. It is provided for
informational purposes only. NORD recommends that affected individuals seek the advice or counsel of
their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms
listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the
topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease
Database completely current and accurate. Please check with the agencies listed in the Resources section
for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization
for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site
www.rarediseases.org or email orphan@rarediseases.org
Last Updated: 9/23/2007
Copyright 1992, 1999, 2006, 2007
National Organization for Rare Disorders, Inc.
|
|
|
This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.
|
|